News | June 03, 2022
Mitsubishi Tanabe Pharma America presents 48-week results from phase 3 safety clinical study of Radicava ORS
Radicava ORS was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2022
Radicava ORS was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2022
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
These and many other questions gather worldwide experts of the pharmaceutical industry at the PHARMAP 2022 which takes place in Berlin, Germany on June, 20 - 21, 2022
Govt. has set a target to increase the number of JanAushadhi Kendras to 10,000 by March 2024
The new Oncology CRO will aim to drive faster execution and higher quality trial outcomes for Oncology sponsors.
Besides enhancing workflow operations by connecting scientists with their lab instruments and data, digitalization holds the potential to acceleratee long-term business growth
120+ members of multi-disciplinary medical team are trained to provide seamless, outcome driven trauma and emergency care
Focussed campaigns for old age homes, schools/colleges, prisons, brick kilns to be taken up by States/UTs
The site, located in Berkeley County, will be operated using the same quality standards as DuPont’s Healthcare Industries Materials Site, the company’s longstanding biopharmaceutical manufacturing site in Hemlock, Michigan
Subscribe To Our Newsletter & Stay Updated
